Acute Respiratory Distress Syndrome (ARDS) is a serious lung condition where the lungs can't provide enough oxygen to the body. This study tests a new drug, rhu-pGSN, to see if it helps people with moderate-to-severe ARDS. Patients in the study have ARDS due to infections like pneumonia and need extra oxygen or machines to help them breathe. The study is double-blind, meaning neither the patients nor the doctors know who gets the real drug or a placebo, which is a harmless substance that looks like the drug.

Eligible patients will receive either the rhu-pGSN drug or a placebo within 48 hours of diagnosis. The drug is given through an intravenous (IV) line for about six days. Researchers will check how many patients survive after 28, 60 days, and also monitor any side effects. The study aims to find out if rhu-pGSN can lower the death rate from ARDS.

• The study lasts about two months, including follow-up checks.
• Participants will receive six doses of the study drug or placebo.
• Safety is monitored by a special team to ensure patient well-being.